W
WAVEMAN · COMPANY
PTCT · Ptc Therapeutics, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+3.01% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET+4.32% 13F +710MSTR+17.56% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475
← ALL COMPANIES

PTCT

PTC THERAPEUTICS, INC.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001070081
FORM 144 · 13☆ WATCH
INSIDER NET · 180D
-$26.4M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
221
13F, latest reported quarter
REVENUE GROWTH
+114.5%
XBRL, annual
NET MARGIN
39.4%
CONVERSIONS · 180D
28
codes C/M, not in net · $7.0M priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$26.4M over 180 days
-$19.8M over 90 days
below 90% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
221 funds added or opened last quarter
more than 89% of Pharma & Biotech
REVENUE
+114.5% year over year
more than 86% of Pharma & Biotech
MARGIN
39.4% net margin
more than 95% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
no short interest reported
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$26.4M across 10 people in 180 days.
221 funds added or opened positions in the latest 13F quarter, of 385 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +36.9%
+36.9%12M
+0%+24%+47%+71%2025-092025-102025-122026-032026-052026-072026-09 2026-04-01 · Almstead Neil Gregory sold $2.7M2025-12-17 · Pauwels Eric sold $2.7M2025-11-25 · Almstead Neil Gregory sold $1.8M2025-11-24 · Almstead Neil Gregory sold $1.7M2025-10-03 · Almstead Neil Gregory sold $1.6M2025-10-03 · Almstead Neil Gregory sold $1.5M2026-06-17 · Utter Christine Marie sold $1.5M2025-09-12 · Boulding Mark Elliott sold $1.4M2026-06-10 · Pauwels Eric sold $1.3M2025-11-25 · Almstead Neil Gregory sold $1.1M2025-09-11 · Boulding Mark Elliott sold $1.1M2026-07-07 · Almstead Neil Gregory sold $1.0M2026-06-25 · Almstead Neil Gregory sold $980.8K2026-03-10 · Okey Stephanie sold $980.0K2026-06-22 · Almstead Neil Gregory sold $977.8K2025-09-08 · Pauwels Eric sold $950.8K2026-06-22 · Almstead Neil Gregory sold $943.6K2026-01-02 · STEELE GLENN JR MD PHD sold $916.2K2026-07-09 · Smith Mary L. sold $900.0K2026-07-06 · Almstead Neil Gregory sold $871.0K2026-04-01 · Almstead Neil Gregory sold $870.8K2026-08-27 · SCHMERTZLER MICHAEL sold $850.7K2025-10-30 · Reeve Emma sold $834.0K2026-07-07 · Almstead Neil Gregory sold $830.7K2025-12-19 · Pauwels Eric sold $818.0K2025-11-21 · Reeve Emma sold $795.0K2025-10-03 · Jacobson Allan Steven sold $780.0K2025-11-25 · Almstead Neil Gregory sold $774.2K2026-07-06 · Almstead Neil Gregory sold $749.9K2026-06-25 · Almstead Neil Gregory sold $726.6K2026-08-04 · Klein Matthew B. sold $705.7K2025-09-09 · SOUTHWELL DAVID P sold $700.1K2026-08-20 · SCHMERTZLER MICHAEL sold $666.7K2026-06-26 · Almstead Neil Gregory sold $658.0K2026-03-05 · Golden Lee Scott sold $633.8K2025-12-30 · Klein Matthew B. sold $619.9K2025-09-11 · Reeve Emma sold $595.0K2025-11-12 · Reeve Emma sold $546.3K2026-08-19 · SCHMERTZLER MICHAEL sold $527.8K2026-05-14 · Klein Matthew B. sold $527.7K2026-07-09 · Smith Mary L. sold $525.1K2026-06-17 · Boulding Mark Elliott sold $518.1K2026-08-19 · Michael Schmertzler filed to sell $3.6M2026-08-17 · Boulding Mark Elliott filed to sell $201.7K2026-08-04 · Klein Matthew B. filed to sell $705.8K2026-07-14 · Gravier Pierre filed to sell $280.7K2026-07-09 · Almstead Neil Gregory filed to sell $222.4K2026-07-09 · Smith Mary L. filed to sell $1.4M2026-07-07 · Almstead Neil Gregory filed to sell $2.2M2026-07-06 · Almstead Neil Gregory filed to sell $1.9M2026-07-06 · Boulding Mark Elliott filed to sell $427.3K2026-06-26 · Almstead Neil Gregory filed to sell $693.1K2026-06-25 · Almstead Neil Gregory filed to sell $1.8M2026-06-24 · Almstead Neil Gregory filed to sell $452.6K2026-06-22 · Almstead Neil Gregory filed to sell $1.9M
INSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $26.4M sold by insiders over 180 days, 221 funds added last quarter, $15.9M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, PTC THERAPEUTICS, INC. insiders sold a net $26.4M of stock across 483 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER
FILED
SHARES
VALUE
SCHMERTZLER MICHAEL
Director
SELL
2026-08-27
11,890.0
$850.7K
SCHMERTZLER MICHAEL
Director
SELL
2026-08-27
610.0
$44.1K
SCHMERTZLER MICHAEL
Director
SELL
2026-08-26
6,874.0
$500.0K
SCHMERTZLER MICHAEL
Director
SELL
2026-08-26
5,626.0
$411.7K
SCHMERTZLER MICHAEL
Director
SELL
2026-08-20
9,419.0
$666.7K
483 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 478 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
BlackRock, Inc.
13,964,554.0 sh
$1.1B
RTW INVESTMENTS, LP
7,746,415.0 sh
$631.9M
Jupiter Topco LLC
7,236,402.0 sh
$590.2M
VANGUARD PORTFOLIO MANAGEMENT LLC
4,928,111.0 sh
$402.0M
STATE STREET CORP
4,598,952.0 sh
$375.1M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
Michael Schmertzler
FILED 2026-08-19
$3.6M
Boulding Mark Elliott
FILED 2026-08-17
$201.7K
Klein Matthew B.
FILED 2026-08-04
$705.8K
Gravier Pierre
FILED 2026-07-14
$280.7K
Almstead Neil Gregory
FILED 2026-07-09
$222.4K
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Invesco S&P SmallCap Health Care ETF
$4.6M POSITION · AS OF 2026-02-28
3.3%
Invesco Biotechnology & Genome ETF
$6.6M POSITION · AS OF 2026-04-30
2.7%
WPG Partners Select Small Cap Value Fund
$5.2M POSITION · AS OF 2026-02-28
2.5%
Pinnacle Focused Opportunities ETF
$1.3M POSITION · AS OF 2026-02-28
2.1%
Guardian Small Cap Value Diversified VIP Fund
$3.1M POSITION · AS OF 2026-03-31
2.1%
Franklin Convertible Securities Fund
$61.0M POSITION · AS OF 2026-04-30
2.1%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 22 registered trials, 6 still enrolling or running — a status change here is dated weeks before the press release
1
Phase 1
0 ACTIVE
6
Phase 2
2 ACTIVE
8
Phase 3
4 ACTIVE
2
Not applicable
0 ACTIVE
5
Multi-phase
0 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Corporate PAC
FEC · the company-connected political action committee's own receipts and spending — committee totals only, never individual donors
Ptc Therapeutics, Inc. Political Action Committee (Ptc-Pac)
CYCLE 2026 · $123K SPENT
$117.0K
FEDERAL ELECTION COMMISSION · MATCHED BY THE PAC'S CONNECTED ORGANISATION
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$1.7B$806.8M$937.8M$698.8M
OPERATING INCOME$866.9M$-302.6M$-439.5M$-447.4M
NET INCOME$683.0M$-363.3M$-626.6M$-559.0M
EPS (DILUTED)7.78-4.73-8.37-7.79
OPERATING CASH FLOW$711.2M$-107.7M$-158.4M$-356.7M
CASH$984.6M$779.7M$594.0M$279.8M
LONG-TERM DEBT—$285.4M$284.2M$571.7M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-05 ALL SYSTEMS LIVE FOR MACHINES →